Showing results (191-200 of 208) with videos related to
Sort By:
Pageof 21
The Journal of Dermatology|February 3, 2025
Guidelines for the management of drug-induced hypersensitivity syndrome 2023Yoshiko Mizukawa, Natsumi Hama, Hiroyuki Niihara, et al.American Journal of Respiratory and Critical Care Medicine|October 11, 2024
Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical TrialTamera J Corte, Juergen Behr, Vincent Cottin, et al.Journal of Gastroenterology|March 4, 2018
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infectionNorio Akuta, Joji Toyota, Yoshiyasu Karino, et al.American Journal of Ophthalmology|May 17, 2015
Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisChie Sotozono, Mayumi Ueta, Eiji Nakatani, et al.Japanese Journal of Cancer Research : Gann|October 3, 2002
U-shaped effect of drinking and linear effect of smoking on risk for stomach cancer in JapanShogo Kikuchi, Toshifusa Nakajima, Osamu Kobayashi, et al.Atherosclerosis|September 18, 2023
Association of thyroid peroxidase antibody with the RNF213 p.R4810K variant in ischemic stroke/transient ischemic attackTakeshi Yoshimoto, Hiroyuki Ishiyama, Yorito Hattori, et al.BMJ Open Respiratory Research|December 31, 2021
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, et al.Journal of Gastroenterology|August 10, 2016
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infectionJoji Toyota, Yoshiyasu Karino, Fumitaka Suzuki, et al.The Journal of Dermatology|May 19, 2015
Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysisMichiko Aihara, Yoko Kano, Hiroyuki Fujita, et al.Neoplasia (New York, N.Y.)|July 6, 2021
Chloride intracellular channel protein 2 is secreted and inhibits MMP14 activity, while preventing tumor cell invasion and metastasisSaya Ozaki, Akihiro Umakoshi, Hajime Yano, et al.Pageof 21